Received: 10 June 2021
Accepted: 9 November 2021
First Online: 3 December 2021
: This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (G412). All study procedures were performed following the Declaration of Helsinki principles.
: Informed consent was obtained from each patient.
: HM, MS, NT, TI, TN, HO, HT, KK, SA, RN, KM, and AM claimed no COI for this work. MT has received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Taisho Pharma Co., Ltd. HY has received lecture fees from Chugai pharmaceuticals and AbbVie, and advisory fees from Janssen pharmaceuticals. Department of Advanced Medicine for Rheumatic Diseases is supported by two local governments in Japan (Nagahama City, Shiga and Toyooka City, Hyogo) and five pharmaceutical companies (Mitsubishi Tanabe Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., Asahi Kasei Pharma Corp. and UCB Japan Co., Ltd.).